Solvonis Therapeutics (DE:J4I)
FRANKFURT:J4I
J4I Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EDT
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
€16.59M
Enterprise Value€12.65M
Total Cash (Recent Filing)€757.00K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-1.92
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding6,806,403,300
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.44
Price to Sales (P/S)0.00
P/FCF Ratio-4.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low debt reduces insolvency and refinancing risk over the next several months. That structural de-leveraging gives management optionality to pursue restructuring, R&D or M&A without immediate debt constraints, supporting operational continuity despite poor earnings.
Growing Equity BaseA meaningfully higher equity cushion provides a durable solvency buffer to absorb ongoing losses and fund near-term operations. This capital base reduces short-term liquidation risk and extends runway for strategic pivots or product redevelopment over the coming months.
Lower Market Volatility (Beta)A sub‑1 beta indicates structurally lower sensitivity to market swings, which can help management execute multi‑month recovery or turnaround plans with less share‑price disruption. Lower systematic volatility also tends to reduce financing cost pressure in stressed markets.
Bears Say
Consistent Operating LossesPersistent operating and net losses erode retained earnings and limit the company's ability to self‑fund operations or investments. Over a 2–6 month horizon continued losses increase the risk of further equity dilution, constrain hiring or R&D, and make achieving scale more difficult.
Negative Cash GenerationOngoing operating cash burn and deteriorating free cash flow create persistent financing needs. That structural cash deficit forces reliance on external capital or asset sales, heightening dilution or solvency risk and reducing the firm's ability to invest in durable growth initiatives.
Revenue CollapseA collapse of reported revenue to near zero removes the firm’s core ability to scale margins or demonstrate product‑market fit. Without durable revenue, recovery depends on rebuilding sales or launching new offerings, a multi‑month structural challenge with high execution risk.
Solvonis Therapeutics News
J4I FAQ
What was Solvonis Therapeutics’s price range in the past 12 months?
Solvonis Therapeutics lowest stock price was €0.01 and its highest was €0.15 in the past 12 months.
What is Solvonis Therapeutics’s market cap?
Solvonis Therapeutics’s market cap is €16.59M.
When is Solvonis Therapeutics’s upcoming earnings report date?
Solvonis Therapeutics’s upcoming earnings report date is Sep 24, 2026 which is in 92 days.
How were Solvonis Therapeutics’s earnings last quarter?
Solvonis Therapeutics released its earnings results on Apr 29, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is Solvonis Therapeutics overvalued?
According to Wall Street analysts Solvonis Therapeutics’s price is currently Overvalued.
Does Solvonis Therapeutics pay dividends?
Solvonis Therapeutics does not currently pay dividends.
What is Solvonis Therapeutics’s EPS estimate?
Solvonis Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solvonis Therapeutics have?
Solvonis Therapeutics has 6,806,403,300 shares outstanding.
What happened to Solvonis Therapeutics’s price movement after its last earnings report?
Solvonis Therapeutics reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Solvonis Therapeutics?
Currently, no hedge funds are holding shares in DE:J4I
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solvonis Therapeutics
Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January 2025, is dedicated to the research and development of advanced polymer modification technologies and techniques. Its operations span the United Kingdom, Slovenia, and across Europe. The company offers a diverse portfolio of specialized products: GRAFTABOND: A line of graft/block copolymers designed to robustly combine various polymers with materials such as fiberglass, carbon fiber, mineral and natural fillers, and even mixed polymer waste. GRAFTALEN: These are reactive solid super-concentrates engineered to enhance polyolefin rheology, boost e-modulus, act as chain extenders for PET/PBT, and serve as AOX masterbatches. GRAFTAPOR: Comprising porous polymer-carriers, this line is specifically developed for applications involving liquid chemicals. GRAFTAMID: This series includes high-temperature elastomers, based on nanostructured polyolefin-polyamide alloys. They function as advanced hardening modifiers within polyamide compounds or as standalone components in hot melt adhesive formulations. GRAFTAKIT: Offering reactive liquid or solid super-concentrates embedded in polymeric porous media, GRAFTAKIT is used to optimize reaction extrusion and the modification of compounds. GRAFTALLOY: A range of polymer-polymer nano-alloys crafted to significantly improve abrasion and temperature resistance, boost impact strength, and reduce friction. GRAFTASYNT: This line encompasses synthetic products, notably including halogen-free flame retardants. GRAFTAMER: An innovative smart polymer characterized by thermo-reversible crosslinking, self-hardening, self-healing properties, and shape memory capabilities. The company was founded in 2017 and maintains its headquarters in London, United Kingdom.
Avingtrans
―
IMI plc
―
Mpac Group PLC
―
Morgan Advanced Materials
―
Smiths Group plc
―
Options Prices
Currently, No data available
---